Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Full vs Fractional CO2 Laser Pretreatment for MAL-PDT in Non-Melanoma Skin Cancer
NCT03012009Completed
- Sponsor
- Ghent University Hospital
- Start
- Sep 2014
- Primary completion
- May 2017
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of methyl aminolevulinate in basal cell carcinoma (BCC) and squamous cell carcinoma in situ (SCCIS) (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Clinical efficacy at 12 months. Started Sep 2014; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)squamous cell carcinoma in situ (SCCIS)
Beyond the preview
Go deeper on NCT03012009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012009.